Overview

The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Beijing Aerospace General Hospital
Beijing Hospital
Beijing Tongren Hospital
Qilu Hospital of Shandong University
The Sixth Medical Center of PLA General Hospital

Treatments:

Dexamethasone
Zanubrutinib